HIV treatment with dolutegravir plus rifampicin during TB care
Part of Infections clinical trials.
This Phase 2 study tests how well and how safely an HIV medicine (dolutegravir) works when given with rifampicin, a common anti-TB medicine, for people starting HIV treatment during TB treatment. It also studies drug levels in the body to help confirm dosing and safety while treating both infections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have documented HIV and are over age 18
- You have not used HIV medicines before (or less than 2 weeks total)
- You also have a confirmed TB diagnosis and will stay on rifampicin-based TB treatment for at least 4 more weeks after starting HIV treatment
- Your recent liver and kidney blood tests are in safe ranges (ALT under 5× the lab’s upper limit; estimated kidney function above 60)
- You don’t have other serious opportunistic infections (with limited exceptions like oral thrush)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a two-drug HIV treatment (dolutegravir and lamivudine) for people who also have active TB and are taking a standard TB medicine called rifampin. It is designed for those who have not yet started HIV treatment.
This study tests how dolutegravir (an HIV medicine) works in children when taken with weekly rifapentine and isoniazid (medicines to prevent tuberculosis). It may help find the right dose for kids who have HIV and are at risk for TB.
This study looks at the right way to dose dolutegravir (an HIV medicine) in young children who also have active tuberculosis (TB). Doctors will measure how the medicine moves through the body, especially when standard vs higher-dose rifampicin is used.
This trial tests whether switching (or continuing) treatment with dolutegravir (DTG) plus lamivudine (3TC) works as well and is better tolerated in adults with HIV that is already controlled. It is specifically for people who have possible kidney (TDF-related) or bone side effects from their current TDF-based regimen.
This trial tests better ways to manage HIV when the virus becomes resistant to dolutegravir (DTG), a key medicine. It is for people with high viral load despite being on DTG for at least six months.
This study compares two different HIV medication regimens in people who have both HIV and active tuberculosis (TB) and are starting HIV treatment for the first time. The goal is to see which combination works better and is safer when taken together with TB medications.
Hear when a new HIV/TB Coinfection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.